Sec Form 4 Filing - Nijhawan Pardeep @ Edesa Biotech, Inc. - 2019-06-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Nijhawan Pardeep 2. Issuer Name and Ticker or Trading Symbol Edesa Biotech, Inc. [ EDSA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O EDESA BIOTECH INC., 100 SPY COURT 3. Date of Earliest Transaction (MM/DD/YY) 06/07/2019 (Street) MARKHAM, A6L3R 5H6 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 06/07/2019 A 507,129 ( 1 ) ( 2 ) A $ 0 507,129 D Common Shares 06/07/2019 A 1,988,424 ( 1 ) ( 2 ) A $ 0 1,988,424 I Held by Pardeep Nijhawan Medicine Professional Corporation ( 3 ) Common Shares 06/07/2019 A 211,506 ( 1 ) ( 2 ) A $ 0 211,506 I Held by The Digestive Health Clinic Inc. ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 0.38 ( 4 ) 06/07/2019 A 44,823 ( 2 ) ( 5 ) ( 6 ) 09/26/2027 Common Shares 44,823 $ 0 44,823 D Stock Option (right to buy) $ 0.38 ( 4 ) 06/07/2019 A 1,529 ( 2 ) ( 5 ) ( 7 ) 12/28/2028 Common Shares 1,529 $ 0 1,529 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Nijhawan Pardeep C/O EDESA BIOTECH INC. 100 SPY COURT MARKHAM, A6L3R 5H6 X X Chief Executive Officer Signatures /s/Pardeep Nijhawan 06/11/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents common shares of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.)(the "Issuer") issued in the share exchange transaction that was completed on June 7, 2019, pursuant to that certain Share Exchange Agreement, dated March 7, 2019, by and among the Issuer, Edesa Biotech Inc. ("Edesa") and the shareholders of Edesa Biotech Inc. ( 2 )All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. ( 3 )Each of Pardeep Nijhawan Medicine Professional Corporation and The Digestive Health Clinic Inc. are wholly-owned by Pardeep Nijhawan. ( 4 )In Canadian currency. ( 5 )This option was issued in replacement of an option to purchase shares of Edesa. ( 6 )This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. ( 7 )This option vests and becomes exercisable 1/3 on 12/28/19, and monthly thereafter through 12/28/21.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.